Medically reviewed by Marla Anderson, MDMultiple myeloma is a rare type of blood cancer that forms in plasma cells, a white ...

Bispecific antibody therapy is transforming cancer treatment, especially in multiple myeloma, with ongoing studies exploring ...

At just 42 years old, Allison Freedman's life took an unexpected and devastating turn. She was a busy mom raising ...

DEAR DR. ROACH: My wife was recently discharged after a lengthy hospital stay with multiple diagnoses. Most of her issues ...

Arcellx's anito-cel shows promising efficacy and safety in multiple myeloma. Read why I maintain my hold rating for ACLX ...

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

AbbVie and Simcere Zaiming have announced a partnership worth over $1bn to develop an investigational drug candidate for ...

In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory drugs achieved an overall response rate of 56.2% and median progression-free ...

Jodie Hill from Wolverhampton was diagnosed with multiple myeloma in March 2021 which was originally suspected to be diabetes ...

A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a ...

For patients with relapsed or refractory multiple myeloma, talquetamab plus teclistamab shows response in a high percentage ...

Subcutaneous Sarclisa, administered via OBDS, showed non-inferior efficacy to IV Sarclisa in relapsed/refractory multiple ...